What Is Can-Fite Biopharma Ltd (CANF) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Can-Fite Biopharma Ltd's intrinsic value is estimated at a composite fair value of $2.07. Trading at $3.24, the stock is approaching fair value or slight overvaluation (implied return of -36.0%), as 6 of 9 models suggest limited further upside. Notably, First Chicago sees the most upside at +46.9% (fair value: $4.76), while Sentiment SOTP is the most conservative at -98.4% ($0.05). The spread between these extremes — +145.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CANF?
9 of 13 models are currently active for CANF. Of these, 3 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates CANF's intrinsic value at $1.46, implying -54.9% downside from the current price. See which stocks rank higher →
How Does CANF Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, CANF ranks #407 by Quality of Company score. CirclFi's QOC score of 2.4/10 evaluates 32 fundamental signals. A score of 2.4 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Can-Fite Biopharma Ltd, metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is CANF a Value Trap?
CirclFi's Value Trap algorithm assigns CANF a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Can-Fite Biopharma Ltd. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Can-Fite Biopharma Ltd scores 2.4 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +145.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CANF valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CANF's 9 active models, average confidence is 13%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad